RCT to Evaluate the Cosmetic Efficacy of Demo-cosmetic Active Ingredient CLS02021

NCT ID: NCT05048121

Last Updated: 2021-09-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-24

Study Completion Date

2021-09-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will explore the potential of probiotic based, novel cosmetic active ingredient to rebuild the collagen based skin barrier with the overall aim to rejuvenate ageing or damaged skin, improve skin integrity, appearance, beauty, and support personal well-being and vitality.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overall Skin Appearance Dry Skin; Eczema

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Infra-subject comparisons study. As the study is intraindividual, every subject will apply study product on the one side of the face and placebo on the other side of the face at the same time. Subject will not be aware what product is the study product and application is indicated only by the side of the face products are applied.
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
Randomized, double blind, placebo controlled. All products will be packed in the identical packaging and will be labeled in accordance to randomization technique.

Label will contain: 4 digit, randomization code of the sample and visible sign "LEFT" or "RIGHT".

Visible sign ''Left'' or ''Right'' will indicate the side of the face the product will be applied.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CLS02021 - Investigational Product arm

Cosmetic cream with proprietary cosmetic ingredient CLS02021.

Group Type EXPERIMENTAL

Cosmetic Active Ingredient CLS02021

Intervention Type OTHER

Topical, face application of the cream base with the CLS02021, two times a day in a period of 30 days

PLC01021 - Placebo Control arm

Cosmetic cream, identical to the studied product but without cosmetic ingredient. Color, texture, scent and the packaging are identical as a IP.

Group Type PLACEBO_COMPARATOR

Placebo PLC01021

Intervention Type OTHER

Topical, face application of the cream base, two times a day in a period of 30 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cosmetic Active Ingredient CLS02021

Topical, face application of the cream base with the CLS02021, two times a day in a period of 30 days

Intervention Type OTHER

Placebo PLC01021

Topical, face application of the cream base, two times a day in a period of 30 days

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and/or female subjects aged 18 to 69 years
2. Subjects who have given and signed written informed consent
3. Subjects who are willing to comply with the study requirements

Exclusion Criteria

1. Subjects with any systemic disorder or face dermatoses including acne that would in any way confound interpretation of the study results (e.g. atopic dermatitis, eczema, or psoriasis)
2. Subjects with a condition or receiving a medication and/or with a history of medical/surgical events which, in the opinion of the Investigator, could compromise the safety of the subject or affect the outcome of the study
3. Subjects with a history of skin cancer
4. Subjects who have started, stopped or changed of hormonal treatment (contraception, thyroid …) in the 3 months prior the study inclusion
5. Subjects who are sensitive to any compound in the base cream
6. Subjects who are sensitive to any active cosmetic compound including Sphingomielinaze, Hylauronic Acid, Lactic Acid or Lipothecoic acid
7. Subjects who have used systemic drugs for more than 3 consecutive days related to antibiotics, anti-inflammatory, corticoids, anti-acneic in the 4 weeks prior to study inclusion
8. Subjects who have used topical drugs for more than 3 consecutive days related to antibiotics, anti-inflammatory, corticoids, anti-acneic in the 4 weeks prior to study inclusion
9. Subjects who have used scrub, anti-seborrheic topical cosmetic products and/or who have applied self-tanning products on face in the 1 week prior the study inclusion
10. Subjects having applied any topical products on face (including make- up) the day of the study inclusion
11. Subjects who have planned a major surgery during the study requiring hospitalization under general anesthesia and the use of systemic or topical drugs (e.g. antibiotics, anti-inflammatory) for more than 1 week
12. Subjects belonging to the staff of the study center
13. Subjects in an exclusion period or participating in another biomedical research study
Minimum Eligible Age

18 Years

Maximum Eligible Age

69 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sarajevo School of Science and Technology, Medical School Department

UNKNOWN

Sponsor Role collaborator

Public Institution Sarajevo Pharmacies

UNKNOWN

Sponsor Role collaborator

Anbiome Labs LLC

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical Department, SSST

Sarajevo, , Bosnia and Herzegovina

Site Status

Public Institution Sarajevo Pharmacies

Sarajevo, , Bosnia and Herzegovina

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Bosnia and Herzegovina

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RCT-CLS0521

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Evaluate the Effect of Synbiotics on MAFLD
NCT06537882 ACTIVE_NOT_RECRUITING NA
Effects of Synbiotics on Obesity
NCT06578143 NOT_YET_RECRUITING PHASE2
The Symbiont-Restore Study
NCT05942586 COMPLETED NA